Enliven Therapeutics, Inc.
ELVN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001672619
In the last 90 days, Enliven Therapeutics, Inc. insiders filed 0 open-market purchases and 8 sales; 214 institutions reported holding it in 13F filings for Q2 2026, worth $4.06B in total; no superinvestor holds it.
13F holders, Q1 2023
Institutional positions in Enliven Therapeutics, Inc. as of Mar 31, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 45
- +9 vs. Q4 2022
- Shares held
- 33.6M
- +15.3M (+84.0%) vs. Q4 2022
- Total value
- $735.0M
- +$660.3M (+884.5%) vs. Q4 2022
- New holders
- 17
- 5 more added
- Sold out
- 8
- 23 more reduced
Compare with Q4 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ELVN on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 214 | $4.06B |
| Q1 2026 | 171 | $2.43B |
| Q4 2025 | 126 | $960.9M |
| Q3 2025 | 134 | $1.22B |
| Q2 2025 | 125 | $1.19B |
| Q1 2025 | 122 | $983.9M |
| Q4 2024 | 114 | $1.12B |
| Q3 2024 | 102 | $1.22B |
| Q2 2024 | 93 | $1.13B |
| Q1 2024 | 74 | $780.8M |
| Q4 2023 | 62 | $539.8M |
| Q3 2023 | 61 | $533.8M |
| Q2 2023 | 63 | $797.9M |
| Q1 2023 | 45 | $735.0M |
| Q4 2022 | 36 | $74.7M |
| Q3 2022 | 31 | $18.8M |
| Q2 2022 | 26 | $13.1M |
| Q1 2022 | 31 | $26.2M |
| Q4 2021 | 35 | $33.6M |
| Q3 2021 | 38 | $62.5M |
| Q2 2021 | 31 | $86.3M |
| Q1 2021 | 40 | $92.9M |
Institutions, Q1 2023
Shares, value and share of portfolio for each institution holding Enliven Therapeutics, Inc.; share changes are against Q4 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| OrbiMed Advisors LLC | 8,996,213 | $197.0M | 3.90% | +4,609,645+105.1% | Added |
| 5AM Venture Management, LLC | 5,798,475 | $127.0M | 32.47% | +5,798,475 | New |
| FMR LLC | 3,163,482 | $69.3M | 0.01% | +3,068,137+3,217.9% | Added |
| Citadel Advisors LLC | 2,296,210 | $50.3M | 0.05% | +1,519,425+195.6% | Added |
| VR Adviser, LLC | 2,214,142 | $48.5M | 9.47% | +2,214,142 | New |
| Ra Capital Management, L.P. | 2,122,465 | $46.5M | 1.05% | −1,128,259−34.7% | Reduced |
| Cormorant Asset Management, LP | 1,936,133 | $42.4M | 2.79% | +1,936,133 | New |
| Fairmount Funds Management LLC | 1,924,938 | $42.2M | 7.25% | +1,293,605+204.9% | Added |
| Commodore Capital LP | 1,731,365 | $37.9M | 5.77% | −763,429−30.6% | Reduced |
| Frazier Life Sciences Management, L.P. | 830,983 | $18.2M | 1.32% | +830,983 | New |
| Boxer Capital, LLC | 710,644 | $15.6M | 0.76% | +710,644 | New |
| Janus Henderson Group PLC | 602,154 | $13.2M | 0.01% | −326,552−35.2% | Reduced |
| Logos Global Management LP | 401,229 | $8.79M | 1.26% | +401,229 | New |
| BML Capital Management, LLC | 212,179 | $4.65M | 4.02% | −2,805,595−93.0% | Reduced |
| Vanguard Group Inc | 151,914 | $3.33M | 0.00% | −289,299−65.6% | Reduced |
| Renaissance Technologies LLC | 70,258 | $1.54M | 0.00% | −143,542−67.1% | Reduced |
| JBF Capital, Inc. | 50,050 | $1.10M | 0.25% | −150,150−75.0% | Reduced |
| Millennium Management LLC | 46,874 | $1.03M | 0.00% | +46,874 | New |
| Goldman Sachs Group Inc | 41,411 | $906.9K | 0.00% | +41,411 | New |
| Geode Capital Management, LLC | 35,388 | $775.0K | 0.00% | −102,338−74.3% | Reduced |
| BlackRock Inc. | 33,795 | $740.1K | 0.00% | −80,755−70.5% | Reduced |
| Acuta Capital Partners, LLC | 30,979 | $678.4K | 0.53% | −13,524−30.4% | Reduced |
| Jane Street Group, LLC | 18,444 | $403.9K | 0.00% | +18,444 | New |
| Bridgeway Capital Management, LLC | 17,950 | $393.1K | 0.01% | −81,750−82.0% | Reduced |
| Morgan Stanley | 17,418 | $381.5K | 0.00% | −39,330−69.3% | Reduced |
| Susquehanna International Group, LLP | 17,167 | $376.0K | 0.00% | +17,167 | New |
| Bank of New York Mellon Corp | 15,295 | $335.0K | 0.00% | −36,732−70.6% | Reduced |
| Mirabella Financial Services LLP | 11,670 | $255.6K | 0.05% | +11,670 | New |
| Citigroup Inc | 11,263 | $246.7K | 0.00% | +11,263 | New |
| Dimensional Fund Advisors LP | 9,915 | $217.1K | 0.00% | −25,976−72.4% | Reduced |
| State Street Corp | 9,424 | $206.4K | 0.00% | −28,274−75.0% | Reduced |
| Cubist Systematic Strategies, LLC | 8,986 | $196.8K | 0.00% | −3,814−29.8% | Reduced |
| Barclays PLC | 7,227 | $158.3K | 0.00% | +7,227 | New |
| Bank of America Corp | 6,545 | $143.3K | 0.00% | +6,315+2,745.7% | Added |
| Prelude Capital Management, LLC | 34,062 | $40.0K | 0.00% | −27,080−44.3% | Reduced |
| Tower Research Capital LLC (TRC) | 1,657 | $36.0K | 0.00% | −2,177−56.8% | Reduced |
| Dorsey Wright & Associates | 1,237 | $27.1K | 0.01% | −4,263−77.5% | Reduced |
| Point72 Asset Management, L.P. | 746 | $16.3K | 0.00% | +746 | New |
| Royal Bank of Canada | 486 | $11.0K | 0.00% | −102−17.3% | Reduced |
| UBS Group AG | 334 | $7.32K | 0.00% | −2,511−88.3% | Reduced |
| Point72 Middle East FZE | 293 | $6.42K | 0.00% | +293 | New |
| Federated Hermes, Inc. | 243 | $5.32K | 0.00% | −797−76.6% | Reduced |
| JPMorgan Chase & Co | 94 | $2.00K | 0.00% | +94 | New |
| Baystate Wealth Management LLC | 50 | $1.09K | 0.00% | +50 | New |
| Wells Fargo & Company | 24 | $526 | 0.00% | −73−75.3% | Reduced |
| Woodline Partners LP | 0 | $0 | 0.00% | −866,405−100.0% | Sold out |
| Diametric Capital, LP | 0 | $0 | 0.00% | −171,942−100.0% | Sold out |
| Marquette Asset Management, LLC | 0 | $0 | 0.00% | −37,745−100.0% | Sold out |
| Northern Trust Corp | 0 | $0 | 0.00% | −26,697−100.0% | Sold out |
| Two Sigma Advisers, LP | 0 | $0 | 0.00% | −25,700−100.0% | Sold out |
| Great Valley Advisor Group, Inc. | 0 | $0 | 0.00% | −13,660−100.0% | Sold out |
| Charles Schwab Investment Management Inc | 0 | $0 | 0.00% | −11,519−100.0% | Sold out |
| Freedom Wealth Alliance, LLC | 0 | $0 | 0.00% | −3,100−100.0% | Sold out |